These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 17072614)

  • 1. Arsenic trioxide induced acute flare-up of rheumatoid arthritis in a patient with APL.
    Naithani R; Mahapatra M; Kumar R; Kumar A; Agrawal N
    Ann Hematol; 2007 Feb; 86(2):151-2. PubMed ID: 17072614
    [No Abstract]   [Full Text] [Related]  

  • 2. Comparing two arsenic trioxide administration methods in APL therapy.
    Zhou J; Meng R; Yang BF
    Chin Med J (Engl); 2004 Sep; 117(9):1411-3. PubMed ID: 15377438
    [No Abstract]   [Full Text] [Related]  

  • 3. Non-lethal bone marrow necrosis under first-line arsenic trioxide therapy in acute promyelocytic leukaemia.
    Ianotto JC; Tempescul A; Eveillard JR; Charles F; Berthou C
    Acta Haematol; 2010; 123(3):146-7. PubMed ID: 20134156
    [No Abstract]   [Full Text] [Related]  

  • 4. Hyperleukocytosis from arsenic trioxide.
    Levy M; Wofford MM; Powell BL; McLean TW
    Pediatr Blood Cancer; 2008 Jun; 50(6):1265-7. PubMed ID: 18300308
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Two cases of monocular visual loss during oral arsenic trioxide therapy of acute promyelocytic leukemia.
    Au WY; Hon C; Yau K; Lai WW; Fong BM; Tam S; Kwong YL
    Am J Hematol; 2009 Oct; 84(10):699. PubMed ID: 19705432
    [No Abstract]   [Full Text] [Related]  

  • 6. All-trans-retinoic acid and arsenic trioxide as initial therapy for acute promyelocytic leukemia.
    Quezada G; Kopp L; Estey E; Wells RJ
    Pediatr Blood Cancer; 2008 Jul; 51(1):133-5. PubMed ID: 18293388
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Arsenic-induced pericardial and pleural effusion without acute promyelocytic leukemia differentiation syndrome.
    Ueda K; Nagai S; Miyashita SI; Kaise T; Ichikawa M; Kumano K; Hangaishi A; Nannya Y; Kurokawa M
    Leuk Res; 2010 Jan; 34(1):e25-6. PubMed ID: 19747729
    [No Abstract]   [Full Text] [Related]  

  • 8. Solid tumors subsequent to arsenic trioxide treatment for acute promyelocytic leukemia.
    Au WY; Kumana CR; Lam CW; Cheng VC; Shek TW; Chan EY; Liu R; Kwong YL
    Leuk Res; 2007 Jan; 31(1):105-8. PubMed ID: 16725199
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Arsenic trioxide: "a successful poison" in patients with acute promyelocytic leukemia].
    Lengfelder E; Schultheis B; Büchner T; Hehlmann R
    Dtsch Med Wochenschr; 2007 Feb; 132(7):330-6. PubMed ID: 17286223
    [No Abstract]   [Full Text] [Related]  

  • 10. Arsenic trioxide in a hemodialytic patient with acute promyelocytic leukemia.
    Yamamoto Y; Sasaki M; Oshimi K; Sugimoto K
    Acta Haematol; 2009; 122(1):52-3. PubMed ID: 19816009
    [No Abstract]   [Full Text] [Related]  

  • 11. Fluid retention during arsenic trioxide treatment in acute promyelocytic leukemia.
    Arai A; Kitano A; Kurosu T; Yamamoto K; Miki T; Murakami N; Miura O
    Am J Hematol; 2005 Jul; 79(3):247-8. PubMed ID: 15981228
    [No Abstract]   [Full Text] [Related]  

  • 12. Arsenic in the cerebrospinal fluid of a patient receiving arsenic trioxide for relapsed acute promyelocytic leukemia with CNS involvement.
    Knipp S; Gattermann N; Schapira M; Käferstein H; Germing U
    Leuk Res; 2007 Nov; 31(11):1585-7. PubMed ID: 17416415
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Arsenic trioxide consolidation in APL.
    Das M
    Lancet Oncol; 2017 Sep; 18(9):e517. PubMed ID: 28803794
    [No Abstract]   [Full Text] [Related]  

  • 14. Evidence for basophilic differentiation of acute promyelocytic leukaemia cells during arsenic trioxide therapy.
    Masamoto Y; Nannya Y; Arai S; Koike Y; Hangaishi A; Yatomi Y; Kurokawa M
    Br J Haematol; 2009 Mar; 144(5):798-9. PubMed ID: 19036092
    [No Abstract]   [Full Text] [Related]  

  • 15. Increased oxidative DNA products in patients with acute promyelocytic leukemia during arsenic therapy.
    Ninomiya M; Kajiguchi T; Yamamoto K; Kinoshita T; Emi N; Naoe T
    Haematologica; 2006 Nov; 91(11):1571-2. PubMed ID: 17082016
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Arsenic trioxide: new preparation. Acute promyelocytic leukaemia: encouraging results but persistent doubts.
    Prescrire Int; 2004 Aug; 13(72):135-7. PubMed ID: 15532137
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Use of arsenic trioxide in a hemodialysis-dependent patient with relapsed acute promyelocytic leukemia.
    Perreault S; Moeller J; Patel K; Eyler R; Pham T; Russell K; Podoltsev N
    J Oncol Pharm Pract; 2016 Aug; 22(4):646-51. PubMed ID: 25972392
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Arsenic-based therapy benefits leukemia patients.
    FDA Consum; 2001; 35(1):4. PubMed ID: 11930925
    [No Abstract]   [Full Text] [Related]  

  • 19. Arsenic trioxide: new clinical experience with an old medication in hematologic malignancies.
    Douer D; Tallman MS
    J Clin Oncol; 2005 Apr; 23(10):2396-410. PubMed ID: 15800332
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Arsenic trioxide in the treatment of acute promyelocytic leukemia. A review of current evidence.
    Sanz MA; Fenaux P; Lo Coco F;
    Haematologica; 2005 Sep; 90(9):1231-5. PubMed ID: 16154847
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.